Alerta

Application of macleaya cordata extract as salmonella type III secretion system inhibitor

Resumen de: CN121287784A

The invention provides a novel application of a macleaya cordata extract as a salmonella type III secretion system (T3SS) inhibitor. Through construction of a chick infection model and in-vitro experiments, the extract is proved to be capable of remarkably reducing the bacterial load of infected chick liver and spleen tissues, relieving tissue pathological damage and reducing inflammatory cell infiltration. Mechanism research shows that the macleaya cordata extract can down-regulate the expression of T3SS key virulence protein SipA in a dose-dependent manner, interfere the function of a secretion system, and further block the secretion and expression of virulence factors. The invention discloses the potential application of the macleaya cordata extract in the aspect of resisting salmonella toxicity for the first time, and provides a development strategy and a technical basis of a T3SS inhibitor from a natural product.

Bacillus velezensis Bv-GD2 and application thereof

Resumen de: CN121294263A

The invention relates to bacillus velezensis Bv-GD2 and application of the bacillus velezensis Bv-GD2. The classification name of the bacillus velezensis Bv-GD2 is bacillus velezensis, and the preservation number of the bacillus velezensis Bv-GD2 is GDMCC No: 66722. The strain is wide in antibacterial spectrum and high in tolerance, has the enzyme production capacity and the antibacterial active substance production capacity, and can remarkably inhibit common intestinal pathogens such as clostridium perfringens, salmonella, staphylococcus aureus and escherichia coli, relieve intestinal lesions, improve the health degree of the intestinal environment and improve the growth performance of livestock and poultry.

SYSTEMS AND METHODS FOR RISK ASSESSMENT FOR ZOONOTIC DISEASE IN ANIMAL POPULATIONS

Resumen de: AU2024277588A1

Systems and methods for assessing risk for zoonotic disease, including salmonella, amongst an animal population at a production facility. A user can provide data in response to a plurality of data entry fields that can, at least partially, pertain to a procedure, operation, and/or equipment at the production facility. For each data entry field, the data provided by the user can be assigned a value. The value can correspond to predetermined value of a predetermined response that is identified as corresponding to the user inputted data. The assigned value can be adjusted by a weighted factor, which may correspond to a predicted impact the actions or information reflected by the user inputted data may have on the prevention of zoonotic disease. The assigned and/or adjusted values can be compiled to generate a risk assessment score, which can be used to determine a food safety index score and/or food safety plan.

INTRANASAL POLYSACCHARIDE CONJUGATE NANOMULSION VACCINES AND METHODS OF USING THE SAME

Resumen de: US20260007731A1

The present invention relates to intranasal bacterial polysaccharide conjugate nanoemulsion vaccines and methods of using the same for inducing an immune response to a bacterial polysaccharide.

ORAL VACCINE

Resumen de: CN120677168A

The present invention relates to a non-viable bacterial cell in which an immunogenic polypeptide fused to an autotransporter comprising a transmembrane linker and a transporter domain is displayed on the surface of the cell, as well as to formulations comprising such non-viable cells. The formulations are useful as oral vaccines.

MICROBIALS FOR BACTERIAL INHIBITION

Resumen de: MX2025014302A

The invention relates to direct-fed microbials for use in <i>E. coli, Salmonella, </i>and/or <i>Clostridium</i> inhibition in animals. More particularly, the invention relates to isolated <i>Bacillus</i> strains CM256 (NRRL No. B-67706), CM857 (NRRL No. B-67705), CM978 (NRRL No. B-67703), CM1004 (NRRL No. B-67708), and MDG1607 (NRRL No. B-67666), and strains having all of the identifying characteristics of these strains, for a use comprising the above-mentioned use. The invention also relates to the use of isolated <i>Bacillus</i> strains CM256 (NRRL No. B-67706), CM857 (NRRL No. B-67705), CM978 (NRRL No. B-67703), and CM1004 (NRRL No. B-67708), and strains having all of the identifying characteristics of these strains, to treat plants having diseases caused by <i>E. coli, Salmonella, </i>and/or <i>Clostridium</i>.<u> </u>

Primer set for detecting pathogens causing Salmonella Enteritis in pigs and Method for detecting pathogens using the same

Resumen de: KR20260003546A

본 발명은 돼지 살모넬라성 장염 유발 병원균을 검출할 수 있는 프라이머 세트에 관한 것으로, 본 발명에 따른 프라이머 세트를 이용하여 중합효소 연쇄반응을 통해 돼지 살모넬라성 장염 유발 병원균을 신속, 정확하게 검출할 수 있고, 검출한계가 낮아 소량의 돼지 가검물 시료로부터 병원균을 검출하여 감염병을 조기에 진단할 수 있다.

C8 esterase activated double-lock chemiluminescent probe, preparation method thereof and application of C8 esterase activated double-lock chemiluminescent probe in preparation of detection kit for detecting salmonella

Resumen de: CN121270430A

The invention relates to the technical field of chemical analysis and detection, and discloses a C8 esterase activated double-lock chemiluminescence probe, a preparation method thereof and application of the C8 esterase activated double-lock chemiluminescence probe in preparation of a salmonella detection kit, the double-lock chemiluminescence probe is DSCP-CBCN, and the structural formula of the double-lock chemiluminescence probe is shown in the specification. The DSCP-CBCN probe is composed of a C8 esterase cleavable substrate, a phenoxy cyclobutane chemiluminophor and a self-eliminating connexon p-hydroxy benzyl alcohol. After the DSCP-CBCN probe and salmonella are incubated, sodium hypochlorite and hydrogen peroxide are added to generate remarkable chemiluminescence, POCT rapid detection of salmonella can be realized by combining a chemiluminescence microplate reader, the bacterial culture time is shortened to 3-7 hours, the limit of detection (LOD) value is as low as 1.9 CFU/mL, and the sensitivity is improved by 1008 times compared with that of a commercial MUCAP probe. The method is suitable for salmonella large-scale screening in the fields of clinical pathogen diagnosis, food safety detection and environmental health monitoring.

Recombinant attenuated salmonella for expressing pseudostellaria canis metalloproteinase TcMMP-13 and application of recombinant attenuated salmonella

Resumen de: CN121265761A

The invention discloses recombinant attenuated salmonella for expressing metalloproteinase TcMMP-13 of ascaris canis and application of the recombinant attenuated salmonella. The recombinant attenuated salmonella is characterized in that the attenuated salmonella expresses the metalloproteinase TcMMP-13. The vaccine has no obvious influence on mouse body health, the insect reduction rate is far higher than the insect reduction rate threshold values of 40% and 50% provided by the World Health Organization (WHO) in schistosome and hookworm vaccine research and development guidelines, and the recombinant attenuated salmonella vector oral vaccine has excellent protection effect and potential application value.

Pediococcus pentosaceus D17-sourced cytoplasmic membrane vesicle and application thereof

Resumen de: CN121249521A

The invention discloses a pediococcus pentosaceus D17-sourced cytoplasmic membrane vesicle and application thereof, and belongs to the technical field of microorganisms. The pediococcus pentosaceus D17 with excellent probiotic characteristics is separated from fresh excrement of Lichuan horses for the first time, the preservation number of the pediococcus pentosaceus D17 is CCTCC (China Center For Type Culture Collection) NO: M20252051, and meanwhile, the application of the pediococcus pentosaceus D17 and the cytoplasmic membrane vesicles of the pediococcus pentosaceus D17 in resisting salmonella infection is researched. Experimental verification shows that the separated and screened pediococcus pentosaceus D17 and the cytoplasmic membrane vesicles thereof have the effect of resisting salmonella infection and can promote expression of tight junction protein, and the treatment effect of the cytoplasmic membrane vesicles derived from the pediococcus pentosaceus D17 is superior to that of the pediococcus pentosaceus D17. Due to the fact that the cytoplasmic membrane vesicles are prepared through centrifugation of bacterial liquid supernatant, the cytoplasmic membrane vesicles are safer and free of drug resistance risks, and a new thought and a new approach are provided for application of the cytoplasmic membrane vesicles sourced from pediococcus pentosaceus to preparation of salmonella infection resisting products.

Antibacterial peptide fragment intercepted from chitinase IDGF4 protein and application of antibacterial peptide fragment in preparation of antibacterial drugs

Resumen de: CN121249627A

The invention discloses an antibacterial peptide fragment intercepted from chitinase IDGF4 protein and application of the antibacterial peptide fragment in preparation of antibacterial drugs. According to the invention, short peptide fragments in chitinase IDGF4 protein are screened, three candidate peptides are obtained through chemical synthesis, the antibacterial performance of the candidate peptides is systematically evaluated, and the evaluation result shows that the peptide fragment with the amino acid sequence as shown in SEQ ID No.2 can effectively inhibit the growth of salmonella and staphylococcus aureus under the concentration of 1mg/mL; the antibacterial effect of the compound is confirmed in inhibition zone experiments, enzyme-labeled turbidimetry and growth curve monitoring, and the compound shows stable and remarkable antibacterial activity and can be used as a novel antibacterial molecule; the invention provides a new candidate sequence for developing the antibacterial peptide with high efficiency and low drug resistance risk, and has application potential in the aspect of preparing clinical antibacterial drugs.

PCR kit for triple PCR detection of escherichia coli, salmonella enteritidis and riemerella anatipestifer and application of PCR kit

Resumen de: CN121249921A

The invention belongs to the technical field of triple PCR detection PCR kits, and particularly relates to a triple PCR detection PCR kit for escherichia coli, salmonella enteritidis and riemerella anatipestifer and application of the triple PCR detection PCR kit. According to the kit, specific primers are designed by taking an escherichia coli alkaline phosphatase gene, a salmonella enteritidis invasion protein A gene and a riemerella anatipestifer helicase gene as target genes, the specific primers comprise a primer pair aiming at the phoA gene, the sequence of an upstream primer phoA-F is 5 '-TACAGGTACTGCGGGCTTATC-3', the sequence of a downstream primer phoA-R is 5 '-CTTACCGGGAATACATCACA-3', and the length of an amplified target fragment is 622bp; according to the primer pair for the invA gene, the sequence of an upstream primer invA-F is 5 '-AAAAGAAGGGTCGTCGTTAG-3', the sequence of a downstream primer invA-R is 5 '-GGAAGGTACTGCCAGAGGTC-3', the length of an amplified target fragment is 801 bp, and according to the primer pair for the dnaB gene, the sequence of an upstream primer dnaB-F is 5 '-GACGCTATATCATAGATTTAAC-3', the sequence of a downstream primer dnaB-R is 5 '-TCCACCGCTATATATTCTAG-3', and the length of the amplified target fragment is 431 bp.

Preparation of hesperidin carbon dots based on PVP modification and application of hesperidin carbon dots to pork preservation

Resumen de: CN121242078A

The invention discloses a preparation method of hesperidin carbon dots based on PVP modification and pork fresh-keeping application, and aims to solve the problems that hesperidin is poor in water solubility and a traditional nano fresh-keeping material is high in toxicity. The preparation method comprises the following steps: dissolving hesperidin and PVP (Polyvinyl Pyrrolidone) in a mass ratio of (1: 0.5)-(1: 2) in 50-70mL of absolute ethyl alcohol, and stirring for 20-40 minutes; and transferring into a high-pressure kettle, carrying out solvothermal reaction at 170-190 DEG C for 8-15 minutes, cooling, centrifuging at 8000-12000 revolutions per minute, filtering at 0.22 mu m, dialyzing the filtrate for 20-30 hours by using a 500Da dialysis bag, carrying out rotary concentration at 40-50 DEG C, and freeze-drying to obtain hesperidin carbon dot powder. The product is spherical, has a particle size of 3.0-4.5 nm, contains hydroxyl, amino and other functional groups, has an ultraviolet absorption peak at 241 nm, and has a maximum emission wavelength of 450 nm under excitation of 507 nm. When pork is preserved, pork slices are soaked in a 1-5 mg/mL carbon dot aqueous solution for 20-40 minutes and stored at 4 DEG C, the effect is optimal when the carbon dot aqueous solution is 5 mg/mL, microorganisms such as salmonella can be inhibited, lipid oxidation is delayed, and the quality guarantee period of the pork is prolonged by 2-3 days. Raw materials are green and cheap, preparati

一种增强TLR5配体活性的鞭毛蛋白突变体及其应用

Resumen de: CN121248735A

本发明属于生物技术领域，具体涉及一种具有增强TLR5配体活性的鞭毛蛋白突变体及其应用。选择鼠伤寒沙门氏菌鞭毛蛋白一个氨基酸突变位点，通过定点突变技术，利用大肠杆菌系统表达重组蛋白，经体外实验验证显示出良好的生物学活性，与野生型鞭毛蛋白突变体相比，能够更好的激活TLR5配体活性，为增强鞭毛蛋白佐剂和疫苗活性提供了良好的基础。

一种改良型鞭毛蛋白及其应用

Resumen de: CN121248736A

本发明属于生物技术领域，具体涉及一种能够增强人源TLR5结合亲和力的鼠伤寒沙门菌鞭毛蛋白及其应用。本发明通过筛选并确定鞭毛蛋白的关键氨基酸突变位点，采用定点突变技术在大肠杆菌系统中实现重组表达。经体外实验验证，该衍生物能够显著激活TLR5配体功能。本发明解决了现有鞭毛蛋白在激活人源TLR5活性方面效果有限的问题，为鞭毛蛋白在疫苗、免疫治疗剂以及放射防护剂领域的应用提供了新的技术方案和理论基础。

OMVOGENIC OUTER MEMBRANE PROTEIN ENGINEERING FOR OUTER MEMBRANE VESICLE PRODUCTION

Nº publicación: WO2026006835A1 02/01/2026

Solicitante:

THE MEDICAL COLLEGE OF WISCONSIN INC [US]
THE TRUSTEES OF THE UNIV OF PENNSYLVANIA [US]
BRIGHAM AND WOMENS HOSPITAL INC [US]
THE MEDICAL COLLEGE OF WISCONSIN, INC,
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA,
BRIGHAM AND WOMEN'S HOSPITAL, INC